Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response
Genomics, Proteomics & Bioinformatics · 30.05.2025 · 23 (2)
DOI: 10.1093/gpbjnl/qzaf028 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Genomics, Proteomics & Bioinformatics, online erschienen am 04.04.2025. Verfasst von Jiaqi Liu und 24 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of M…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell-Free Nucleic Acids, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program of Science and Technology, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
The fragmentomics-based cell-free DNA (cfDNA) assays have recently illustrated prominent abilities to identify various cancers from non-conditional healthy controls, while their accuracy for identifying early-stage cancers from benign lesions with inconclusive imaging results remains uncertain. Especially for breast cancer, current imaging-based screening methods suffer from high false positive rates for women with breast nodules, leading to unnecessary biopsies, which add to discomfort and healthcare burden. Here, we enrolled 613 female participants in this multi-center study and demonstrated that cfDNA fragmentomics (cfFrag) is a robust non-invasive biomarker for breast cancer using whole-genome sequencing. Among the multimodal cfFrag profiles, the fragment size ratio (FSR), fragment size distribution (FSD), and copy number variation (CNV) show more distinguishing ability than Griffin, motif breakpoint (MBP), and neomer. The cfFrag model using the optimal three fragmentomics features discriminated early-stage breast cancer from benign nodules, even at a low sequencing depth (3×). Notably, it demonstrated a specificity of 94.1% in asymptomatic healthy women at a 90% sensitivity for breast cancer. Moreover, we comprehensively showcased the clinical utility of the cfFrag model in predicting patient responses to neoadjuvant chemotherapy (NAC) and its enhanced performance when combined with multimodal features, including radiological results [area under the curve (AUC) = 0.93–0.94] and cfDNA methylation features (AUC = 0.96).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, Chin…
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
- Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Department of Breast Surgery, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai 264000, China.
- Nanjing Geneseeq Technology Inc., Nanjing 210061, China.
- Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
ORCID-Profile: Jiaqi Liu, Yalun Li, Wanxiangfu Tang, Tianyi Qian, Lijun Dai, Ziqi Jia, Heng Cao, Chenghao Li, Yuchen Liu, Yansong Huang, Jiang Wu, Dongxu Ma, Guangdong Qiao, Hua Bao, Shuang Chang, Dongqin Zhu, Shanshan Yang, Xuxiaochen Wu, Xue Wu, Hengyi Xu, Hongyan Chen, Yang Shao, Xiang Wang, Zhihua Liu, Jianzhong Su
Förderung
- National Natural Science Foundation of China
- Beijing Nova Program of Science and Technology
- CAMS Innovation Fund for Medical Sciences
- Biomedical Big Data Intelligent Computing Center of Oujiang Lab
Zitieren
APA
Liu, J., Li, Y., Tang, W., Qian, T., Dai, L., Jia, Z., Cao, H., Li, C., Liu, Y., Huang, Y., Wu, J., Ma, D., Qiao, G., Bao, H., Chang, S., Zhu, D., Yang, S., Wu, X., Wu, X., …, & Su, J. (2025). Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response. Genomics, Proteomics & Bioinformatics, 23(2). https://doi.org/10.1093/gpbjnl/qzaf028
Vancouver
Liu J, Li Y, Tang W, Qian T, Dai L, Jia Z, et al. Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response. Genomics, Proteomics & Bioinformatics. 2025;23(2). doi:10.1093/gpbjnl/qzaf028
BibTeX
@article{Liu2025,
author = {Liu, Jiaqi and Li, Yalun and Tang, Wanxiangfu and Qian, Tianyi and Dai, Lijun and Jia, Ziqi and Cao, Heng and Li, Chenghao and Liu, Yuchen and Huang, Yansong and Wu, Jiang and Ma, Dongxu and Qiao, Guangdong and Bao, Hua and Chang, Shuang and Zhu, Dongqin and Yang, Shanshan and Wu, Xuxiaochen and Wu, Xue and Xu, Hengyi and Chen, Hongyan and Shao, Yang and Wang, Xiang and Liu, Zhihua and Su, Jianzhong},
title = {Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response},
journal = {Genomics, Proteomics & Bioinformatics},
year = {2025},
volume = {23},
number = {2},
doi = {10.1093/gpbjnl/qzaf028}
}
EUVIMED